Hepatitis C: Diagnosis and treatment

American Family Physician

Volumn 81, Issue 11, 2010, Pages 1351-1357

  Wilkins, Thad ^a   Malcolm, Jennifer K ^a   Raina, Dimple ^a   Schade, Robert R ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ABDOMINAL DISCOMFORT; ACUTE PSYCHOSIS; ALCOHOLISM; AMNESIA; ANEMIA; ANGER; ANGINA PECTORIS; ANOREXIA; ANTIVIRAL THERAPY; ANXIETY; ANXIETY DISORDER; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; COMA; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONFUSION; DEPRESSION; DIARRHEA; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; GASTROINTESTINAL DISEASE; HAIR LOSS; HEARING LOSS; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMOLYSIS; HEPATITIS C; HUMAN; IMMUNOBLOTTING; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE ABSCESS; INTRAVENOUS DRUG ABUSE; IRRITABILITY; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG INSUFFICIENCY; MALAISE; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NEEDLESTICK INJURY; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NOSE CONGESTION; PANIC; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; POLYMERASE CHAIN REACTION; PROGNOSIS; PRURITUS; RETINA HEMORRHAGE; RISK ASSESSMENT; SCREENING TEST; SEIZURE; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; STROKE; SUICIDAL IDEATION; SUICIDE ATTEMPT; THROMBOCYTOPENIA; TINNITUS; UNSPECIFIED SIDE EFFECT; VIRUS DETECTION; VIRUS LOAD; VISUAL IMPAIRMENT; ADULT; DRUG EFFECT; FEMALE; GENETICS; HEPATITIS C VIRUS; MALE; MIDDLE AGED; REVIEW; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIRAL LOAD;

EID: 77953704766     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. World Health Organization. Hepatitis C. Fact sheet N°164. Revised October 2000. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed March 5, 2009.
2. Chou R, Clark EC, Helfand M; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(6):465-479.
3. Jou JH, Muir AJ. In the clinic. Hepatitis C. Ann Intern Med. 2008;148(11):ITC6-1-ITC6-16.
4. Alter MJ. Epidemiology of hepatitis C. Eur J Gastroenterol Hepatol. 1996;8(4):319-323.
5. Distributions of hepatitis C genotypes from Epidemiology of Infectious Diseases. Baltimore, Md.: Johns Hopkins Bloomberg School of Public Health; 2007. http://ocw.jhsph.edu. Accessed March 26, 2009.
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-1492.
7. Wasley A, Grytdal S, Gallagher K; Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ. 2008;57(2):1-24.
8. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group. Hepatology. 1996;24(5):979-986.
9. Donahue JG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327(6):369-373.
10. U.S. Preventive Services Task Force. Screening for hepatitis C in adults. Rockville, Md.: Agency for Healthcare Research and Quality, November 2004. http://www.ahrq.gov/clinic/uspstf/uspshepc.htm. Accessed December 4, 2009.
11. Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol. 2008;103(1):131-137.
12. Koff RS, Muir A. Hepatitis C. In: PIER [online database]. Philadelphia, Pa.: American College of Physicians; 2008. Accessed December 1, 2008.
13. U.S. Public Heatlh Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR-11):1-52.
14. Jaeckel E, Cornberg M, Wedemeyer H, et al.; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452-1457.
15. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
16. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-832.
17. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat. 2002;9(3):235-241.
18. Bruix J, Sherman M; Practice Guidelines Committee and American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236.
19. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 suppl 1):S27-S34.
20. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750.
21. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37-47.
22. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417-422.
23. Centers for Disease Control and Prevention. Reference for interpretation of hepatitis C virus (HCV) test results.: http://www.cdc.gov/Hepatitis/HCV/PDFs/hcv_graph.pdf. Accesssed March 5, 2009.
24. National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36(5 suppl 1):S3-S20.
25. González V, Martró E, Folch C, et al. Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. Eur J Clin Microbiol Infect Dis. 2008;27(2):121-126.
26. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297(7):724-732.
27. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C; HEPATITIS Group. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat. 2001;8(2):87-95.
28. Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006;332(7548):1013-1017.
29. Bruno S, Stroffolini T, Colombo M, et al.; Italian Association of the Study of the Liver Disease. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45(3):579-587.
30. Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13(6):409-414.
31. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47(1):43-50.
32. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171.
33. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46(1):37-47.
34. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat. 2010;17(2):139-147.
35. Metwally MA, Zein CO, Zein NN. Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci. 2007;52(2):582-588.
36. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996;125(8):634-639.
37. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
38. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965.
39. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev. 2009;(4):CD005527.
40. McHutchison JG, Lawitz EJ, Shiffman ML, et al.; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-593.
41. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355(23):2444-2451.
42. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol. 2005;39(1 suppl):S23-S27.
43. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety. 1998;7(4):188-193.
44. Cholongitas E, Papatheodoridis GV. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther. 2008;27(10):866-884.
45. Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008;41(1):50-59.